Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced that Nathan Dowden, Chief Operating Officer, will virtually present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be accessible starting September 12, 2022, at 7:00 a.m. Eastern Time on the company's website. A replay will be available for 90 days after the event. Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics for treating diseases including Duchenne muscular dystrophy and myotonic dystrophy.

BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Nathan Dowden, Chief Operating Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 – 14, 2022.

The company’s presentation will be available to view beginning on Monday, September 12, 2022 at 7:00 a.m. Eastern Time on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com

FAQ

What is the date of Entrada Therapeutics' presentation at the H.C. Wainwright conference?

Entrada Therapeutics will present virtually at the H.C. Wainwright conference from September 12-14, 2022.

Where can I watch Entrada Therapeutics' presentation?

The presentation will be available on Entrada Therapeutics' website starting September 12, 2022, at 7:00 a.m. Eastern Time.

What is the focus of Entrada Therapeutics' EEV™ therapeutics?

Entrada Therapeutics focuses on developing EEV™ therapeutics to treat neuromuscular diseases, immunology, oncology, and central nervous system diseases.

What are the lead programs of Entrada Therapeutics?

Entrada's lead programs include ENTR-601-44 for Duchenne muscular dystrophy and ENTR-701 for myotonic dystrophy type 1.

How long will the replay of the presentation be available?

A replay of the presentation will be available for 90 days following the event.